Johnson & Johnson’s Covid-19 vaccine paused by CDC and FDA due to concerns on blood clots


The CDC and FDA decided late last night to pause the use of the Johnson & Johnson Covid-19 vaccine. This decision was taken after six cases of a rare and severe type of blood clot were reported in the U.S… These cases were reported after more than 6.8 million doses of the vaccine have been administered across the nation.


Women between the ages of 18 and 48 developed blood clots. These clots appeared 6 to 13 days after they had been vaccinated according to a joint statement released by the FDA and the CDC. The health agencies have decided to proceed with caution as of now while they review the cases in detail on Wednesday.


As a result of this announcement by the FDA and the CDC mass vaccinations at sites using the Johnson and Johnson vaccine will be temporarily stopped. The federal health agencies are also advising the states to halt the administration of these vaccines but said that it was up to the individual states to do so.


While officials maintain that it is a rare occurrence, they also require health care providers to take time to understand the potential side effects and how to properly treat these effects. The pause had occurred as this side effect has not been listed when emergency approval was granted to the vaccine.


In a statement, Johnson & Johnson addressed the people who have taken their shot. The company said that those who have developed the following symptoms: severe headaches, abdominal pain, shortness of breath or leg pain after being vaccinated within a period of three weeks must contact their health care provider. The statement also reiterated that it is a rare event.


The Johnson & Johnson vaccine is an adenovirus vector vaccine. It is similar to the AstraZeneca vaccine that has been rolled out in the U.K., India, Europe and about 70 more countries. A few rare cases were of blood clots among women were also seen mainly in Europe after the administration of the AstraZeneca vaccine. However, the WHO had said that the benefits outweigh the rare cases of clots. The vaccine mentioned the side effect in later batches.


Follow us on Google news for more updates and News


This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.

Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.

Full Disclaimer